T-Rex 2X Long MSTR Daily Target ETF vs Twist Bioscience Corp — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $40.74 (market cap $809.00M), while Twist Bioscience Corp trades at $163 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 12.5× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Twist Bioscience Corp for 27 Days on average.
| MSTU | TWST | |
|---|---|---|
Market Cap | $809.00M | $10.08B |
Volume | 4,577,465 | 4,229,037 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $205.00 |
52-Week Low | $14.60 | $25.45 |
Typical Hold Time | 18 Days | 27 Days |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $39.54, showing minimal daily movement with a 0.23% gain. The technical outlook is bearish based on moving averages, while oscillators present a neutral stance. Recent corporate actions include a 10:1 reverse stock split and a $0.29 dividend scheduled for August 2026. News coverage highlights the ETF's leveraged nature and recent volatility concerns.
The outlook remains cautious due to the bearish technical signals and leveraged ETF structure, which amplifies volatility. Investment opportunities exist for tactical traders seeking short-term momentum, but risks include daily rebalancing effects and potential value erosion during sustained market moves.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →